User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.

Primary tabs

Carrasco, Javier Gizzi, Marco Pairet, Géraldine [UCL] Lannoy, Valérie [UCL] Lefesvre, Pierre Gigot, Jean-François [UCL] Hubert, Catherine [UCL] Mourin, Anne [UCL] Humblet, Yves [UCL] Sempoux, Christine [UCL] Danse, Etienne [UCL] Navez, Benoît [UCL] Van den Eynde, Marc [UCL]

(eng) BACKGROUND: Optimal preoperative treatment before colorectal cancer metastases (CRCM) resection remains unclear. This study evaluated pathological responses (pR) in CRCM resected after chemotherapy alone or combined with angiogenesis or epidermal growth factor receptor (EGFR) inhibitors. METHODS: Pathological response was retrospectively evaluated on 264 resected metastases from 99 patients. The proportion of responding metastases after different preoperative treatments was reported and compared. Patient's progression-free survival (PFS) and overall survival (OS) were compared based on pR. RESULTS: The combination of anti-angiogenics with oxaliplatin-based chemotherapy resulted in more pR than when they were combined with irinotecan-based chemotherapy (80% vs 50%; P<0.001). Inversely, the combination of EGFR inhibitors with oxaliplatin-based chemotherapy seemed to induce fewer pR than when they were combined with irinotecan-based treatment (53% vs 72%; P=0.049). Overall survival at 5 years was improved for patients with a pR in all resected metastases compared with those who did not achieve a pR (68.5% vs 32.6%; P=0.023) and this response was the only factor predicting OS in a multivariate analysis. CONCLUSION: The chemotherapy partner combined with angiogenesis or EGFR inhibitors influenced pR in resected CRCM. In our exploratory analysis anti-angiogenic/oxaliplatin-based regimens and anti-EGFR/irinotecan-based regimens were associated with the highest pR. Prospective randomised trials should be performed to validate these observations.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2015
Language Anglais
Journal information "The British journal of cancer" - Vol. 113, no. 9, p. 1298-1304 (2015)
Peer reviewed yes
Publisher Nature Publishing Group on behalf of Cancer Research UK ((United Kingdom) London)
issn 0007-0920
e-issn 1532-1827
Publication status Publié
Affiliations UCL - (SLuc) Service d'anatomie pathologique
UCL - (SLuc) Unité d'oncologie médicale
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service de chirurgie et transplantation abdominale
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale
UCL - (SLuc) Service de radiologie
UCL - SSS/IREC - Institut de recherche expérimentale et clinique
UCL - (SLuc) Service d'hépato-gastro-entérologie
Keywords pathological response ; colorectal cancer ; targeted therapy ; liver metastases ; surgical resection
Links
  1. Abdalla Eddie K., Vauthey Jean-Nicolas, Ellis Lee M., Ellis Vickie, Pollock Raphael, Broglio Kristine R., Hess Kenneth, Curley Steven A., Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases : , 10.1097/01.sla.0000128305.90650.71
  2. Adam Ren??, Pascal Gerard, Castaing Denis, Azoulay Daniel, Delvart Valerie, Paule Bernard, Levi Francis, Bismuth Henri, Tumor Progression While on Chemotherapy : A Contraindication to Liver Resection for Multiple Colorectal Metastases?, 10.1097/01.sla.0000145964.08365.01
  3. Adam Ren??, Pascal Gerard, Castaing Denis, Azoulay Daniel, Delvart Valerie, Paule Bernard, Levi Francis, Bismuth Henri, Tumor Progression While on Chemotherapy : A Contraindication to Liver Resection for Multiple Colorectal Metastases?, 10.1097/01.sla.0000145964.08365.01
  4. Allen P, Importance of Response to Neoadjuvant Chemotherapy in Patients Undergoing Resection of Synchronous Colorectal Liver Metastases, 10.1016/s1091-255x(02)00121-x
  5. Blazer Dan G., Kishi Yoji, Maru Dipen M., Kopetz Scott, Chun Yun Shin, Overman Michael J., Fogelman David, Eng Cathy, Chang David Z., Wang Huamin, Zorzi Daria, Ribero Dario, Ellis Lee M., Glover Katrina Y., Wolff Robert A., Curley Steven A., Abdalla Eddie K., Vauthey Jean-Nicolas, Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases, 10.1200/jco.2008.17.5299
  6. Yu Oriana, Eberg Maria, Benayoun Serge, Aprikian Armen, Batist Gerald, Suissa Samy, Azoulay Laurent, Use of Statins and the Risk of Death in Patients With Prostate Cancer, 10.1200/jco.2013.49.4757
  7. Diehl Frank, Schmidt Kerstin, Choti Michael A, Romans Katharine, Goodman Steven, Li Meng, Thornton Katherine, Agrawal Nishant, Sokoll Lori, Szabo Steve A, Kinzler Kenneth W, Vogelstein Bert, Diaz Jr Luis A, Circulating mutant DNA to assess tumor dynamics, 10.1038/nm.1789
  8. Douillard Jean-Yves, Oliner Kelly S., Siena Salvatore, Tabernero Josep, Burkes Ronald, Barugel Mario, Humblet Yves, Bodoky Gyorgy, Cunningham David, Jassem Jacek, Rivera Fernando, Kocákova Ilona, Ruff Paul, Błasińska-Morawiec Maria, Šmakal Martin, Canon Jean Luc, Rother Mark, Williams Richard, Rong Alan, Wiezorek Jeffrey, Sidhu Roger, Patterson Scott D., Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer, 10.1056/nejmoa1305275
  9. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  10. Gervaz Pascal, Rubbia-Brandt Laura, Andres Axel, Majno Pietro, Roth Arnaud, Morel Philippe, Mentha Gilles, Neoadjuvant Chemotherapy in Patients with Stage IV Colorectal Cancer: A Comparison of Histological Response in Liver Metastases, Primary Tumors, and Regional Lymph Nodes, 10.1245/s10434-010-1056-6
  11. Heijmen Linda, ter Voert Edwin E. G. W., Oyen Wim J. G., Punt Cornelis J. A., van Spronsen Dick Johan, Heerschap Arend, de Geus-Oei Lioe-Fee, van Laarhoven Hanneke W. M., Multimodality Imaging to Predict Response to Systemic Treatment in Patients with Advanced Colorectal Cancer, 10.1371/journal.pone.0120823
  12. Heinemann V., Modest D., Fischer von Weikersthal L., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S-E., Heintges T., Lerchenmüller C., Kahl C., Seipelt G., Kullmann F., Stauch M., Scheithauer W., Held S., Giessen C., Möhler M., Jagenburg A., Stintzing S., O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306), 10.1093/annonc/mdu193.30
  13. Heinemann Volker, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmüller Christian, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Scheithauer Werner, Hielscher Jörg, Scholz Michael, Müller Sebastian, Link Hartmut, Niederle Norbert, Rost Andreas, Höffkes Heinz-Gert, Moehler Markus, Lindig Reinhard U, Modest Dominik P, Rossius Lisa, Kirchner Thomas, Jung Andreas, Stintzing Sebastian, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, 10.1016/s1470-2045(14)70330-4
  14. Junttila Melissa R., de Sauvage Frederic J., Influence of tumour micro-environment heterogeneity on therapeutic response, 10.1038/nature12626
  15. Nordlinger Bernard, Sorbye Halfdan, Glimelius Bengt, Poston Graeme J, Schlag Peter M, Rougier Philippe, Bechstein Wolf O, Primrose John N, Walpole Euan T, Finch-Jones Meg, Jaeck Daniel, Mirza Darius, Parks Rowan W, Collette Laurence, Praet Michel, Bethe Ullrich, Van Cutsem Eric, Scheithauer Werner, Gruenberger Thomas, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, 10.1016/s0140-6736(08)60455-9
  16. Nordlinger Bernard, Sorbye Halfdan, Glimelius Bengt, Poston Graeme J, Schlag Peter M, Rougier Philippe, Bechstein Wolf O, Primrose John N, Walpole Euan T, Finch-Jones Meg, Jaeck Daniel, Mirza Darius, Parks Rowan W, Mauer Murielle, Tanis Erik, Van Cutsem Eric, Scheithauer Werner, Gruenberger Thomas, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, 10.1016/s1470-2045(13)70447-9
  17. Pietrantonio Filippo, Mazzaferro Vincenzo, Miceli Rosalba, Cotsoglou Christian, Melotti Flavia, Fanetti Giuseppe, Perrone Federica, Biondani Pamela, Muscarà Cecilia, Di Bartolomeo Maria, Coppa Jorgelina, Maggi Claudia, Milione Massimo, Tamborini Elena, de Braud Filippo, Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases, 10.1007/s12032-015-0638-3
  18. Rubbia-Brandt L, Giostra E, Brezault C, Roth A., Andres A, Audard V, Sartoretti P, Dousset B, Majno P., Soubrane O, Chaussade S, Mentha G, Terris B, Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery, 10.1093/annonc/mdl386
  19. Schwartzberg Lee S., Rivera Fernando, Karthaus Meinolf, Fasola Gianpiero, Canon Jean-Luc, Hecht J. Randolph, Yu Hua, Oliner Kelly S., Go William Y., PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer, 10.1200/jco.2013.53.2473
  20. Siravegna Giulia, Mussolin Benedetta, Buscarino Michela, Corti Giorgio, Cassingena Andrea, Crisafulli Giovanni, Ponzetti Agostino, Cremolini Chiara, Amatu Alessio, Lauricella Calogero, Lamba Simona, Hobor Sebastijan, Avallone Antonio, Valtorta Emanuele, Rospo Giuseppe, Medico Enzo, Motta Valentina, Antoniotti Carlotta, Tatangelo Fabiana, Bellosillo Beatriz, Veronese Silvio, Budillon Alfredo, Montagut Clara, Racca Patrizia, Marsoni Silvia, Falcone Alfredo, Corcoran Ryan B, Di Nicolantonio Federica, Loupakis Fotios, Siena Salvatore, Sartore-Bianchi Andrea, Bardelli Alberto, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, 10.1038/nm.3870
  21. Stremitzer S., Stift J., Singh J., Starlinger P., Gruenberger B., Tamandl D., Gruenberger T., Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases, 10.1016/j.ejso.2015.03.223
Bibliographic reference Carrasco, Javier ; Gizzi, Marco ; Pairet, Géraldine ; Lannoy, Valérie ; Lefesvre, Pierre ; et. al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.. In: The British journal of cancer, Vol. 113, no. 9, p. 1298-1304 (2015)
Permanent URL http://hdl.handle.net/2078.1/166581